期刊文献+

培美曲塞和吉西他滨分别联合顺铂治疗晚期肺腺癌近期疗效及毒副反应情况探讨 被引量:1

Observation on Short-term Curative Effect and Side and Toxic Effect of Pemetrexed Combined with Cis-platinum and Gemcitabine Combined with Cis-platinum in Treatment of Advanced Lung Adenocarcinoma
下载PDF
导出
摘要 目的对比培美曲塞联合顺铂、吉西他滨联合顺铂2种治疗方案对晚期肺腺癌的近期疗效及不良反应,以指导临床药物选择。方法方便2012年10月—2015年10月该院收治的晚期肺腺癌(ⅢB期及Ⅳ期)患者80例,按治疗方案划分为2组:观察组应用培美曲塞联合顺铂治疗;对照组应用吉西他滨联合顺铂治疗。均化疗2个周期后,评估并对比疗效及毒副反应。结果观察组总缓解率30.0%、总控制率67.5%,对照组总缓解率27.5%、总控制率70.0%,2组近期疗效差异无统计学意义(P>0.05);观察组白细胞下降、血小板下降及脱发发生率分别为12.5%、7.5%、10.0%,明显低于对照组42.5%、37.5%、37.5%,差异有统计学意义(P<0.05),2组其它不良反应发生率差异无统计学意义(P>0.05)。结论培美曲塞联合顺铂治疗晚期肺腺癌可取得与吉西他滨联合顺铂相近的疗效,且其耐受性优于后者,有一定推广价值。 Objective To compare the short-term curative effect and side and toxic effect of pemetrexed combined with cisplatinum and gemcitabine combined with cis-platinum in treatment of advanced lung adenocarcinoma in order to guide clinical drug selection.Methods 80 cases of patients with advanced lung adenocarcinoma(ⅢB stage and Ⅳ stage) admitted and treated in our hospital from October 2012 to October 2015 were divided into two groups according to different treatment programs,the observation group were treated with pemetrexed combined with cis-platinum,the control group were treated with gemcitabine combined with cis-platinum,and the curative effect and side and toxic effect of the two groups were evaluated and compared after 2 weeks of chemotherapy.Results The total remission rate and total control rate were respectively 30.0% and 67.5% in the observation group and 27.5% and 70.0% in the control group,and the difference in the short-term curative effect between the two groups had no statistical significance,P〉0.05;the incidence rates of leukocyte decrease,platelet decrease and alopecia in the observation group were obviously lower than those in the control group,(12.5%,7.5%,10.0% vs 42.5%,37.5%,37.5%),and the differences had statistical significance,P〈0.05,and the difference in the incidence rate of side and toxic effect between the two groups had no statistical significance,P〉0.05.Conclusion The curative effect of pemetrexed combined with cis-platinum in treatment of advanced lung adenocarcinoma is similar to that of gemcitabine combined with cis-platinum,and the tolerance of it is better than that of the latter,which is of a certain promotion value.
作者 施晓婧
出处 《中外医疗》 2016年第15期127-128,共2页 China & Foreign Medical Treatment
关键词 培美曲塞 吉西他滨 顺铂 肺腺癌 晚期肿瘤 化疗 Pemetrexed Gemcitabine Cis-platinum Lung adenocarcinoma Advanced tumor Chemotherapy
  • 相关文献

参考文献10

二级参考文献109

  • 1李树婷,马飞,孙燕.抗肿瘤代谢新药——培美曲塞[J].癌症进展,2005,3(5):471-476. 被引量:73
  • 2徐磊,赵松,党丽峰,齐宇,杨洋,刘东雷,吴恺,王啸林,鲍培龙.自噬在厄洛替尼诱导的肺腺癌细胞A549凋亡中的作用[J].中国老年学杂志,2014,34(8):2197-2198. 被引量:1
  • 3鲍云华,李俭杰.介绍新的实体瘤治疗反应评价标准(RECIST)[J].中国肺癌杂志,2005,8(1):77-78. 被引量:112
  • 4汤钊猷.现代肿瘤学[M].3版.上海:复旦大学出版社,2011:890-931.
  • 5彭红.肺癌住院病例的流行病学特征及预后随访研究[D].复旦大学,2010.
  • 6Scagliotti GV,Parikh P, von Pawel J, et al. Phase HI studycomparing cisplatin plus gemcitabine with cisplatin plus perae-trexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer [ J ]. J Clin Oncol, 2008,26(21) :3543-3551.
  • 7National Comprehensive Cancer Network. 2011 年 NCCN 非细胞肺癌临床实践指南(中国版)[EB/OL]. [2012-06-10]. ht-tp://www. nccnchina. org/nccn-guidelines-china. aspx.
  • 8Sandomenico C,Costanzo R,Carillio G,et al. Bevacizumab innon small cell lung cancer : development, current status and is-sues[J]. Curr Med Chem, 2012, 19(7) :961 -971.
  • 9Chattoopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanismsand clinial appli- cations [ J ] . Mol Cancer Ther, 2007, 6 (2) : 404 -417.
  • 10Racanelli AC, Rothbart SB, Heyer CL, et al. Therapeutics by cytotoxic metabolite accumula- tion: pemetrexed causes ZMP accumulation AMPK activation and mammalian target or ra- pamycin inhibition [ J ] . Cancer Res, 2009, 69 (13): 5467-5474.

共引文献102

同被引文献2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部